Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease | Zendy

Michael Egan | Zendy; James Kost | Zendy; Pierre N. Tariot | Zendy; Paul Aisen | Zendy; Jeffrey L. Cummings | Zendy; Bruno Vellas | Zendy; Cyrille Sur | Zendy; Yuki Mukai | Zendy; Tiffini Voss | Zendy; Christine Furtek | Zendy; Erin Mahoney | Zendy; Lyn Harper Mozley | Zendy; Rik Vandenberghe | Zendy; Mo Yi | Zendy; David Michelson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Author(s) -

Michael Egan,

James Kost,

Pierre N. Tariot,

Paul Aisen,

Jeffrey L. Cummings,

Bruno Vellas,

Cyrille Sur,

Yuki Mukai,

Tiffini Voss,

Christine Furtek,

Erin Mahoney,

Lyn Harper Mozley,

Rik Vandenberghe,

Mo Yi,

David Michelson

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1706441

Subject(s) - randomized controlled trial , alzheimer's disease , medicine , disease , psychology

Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) followed by γ-secretase. Verubecestat is an oral BACE-1 inhibitor that reduces the Aβ level in the cerebrospinal fluid of patients with Alzheimer's disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research